What Researchers Did
Researchers investigated the clinical and biochemical effects of hyperbaric oxygen therapy (HBOT) in 50 hospitalized COVID-19 patients with hypoxemic respiratory failure, comparing it to standard care.
What They Found
Patients receiving HBOT reached oxygen saturation >90% in 3 ± 1 days, compared to 5 ± 1 days for standard care (P < 0.01). HBOT also significantly reduced D-dimer levels (P < 0.001), LDH concentration (P < 0.01), and inflammatory markers like sVCAM, sPselectin, SAA, and TNFα.
What This Means for Canadian Patients
Hyperbaric oxygen therapy could potentially accelerate recovery of oxygen levels and reduce inflammation in Canadian patients hospitalized with severe COVID-19. This may lead to shorter hospital stays and improved clinical outcomes for those experiencing hypoxemic respiratory failure.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
This study was limited by its short-term follow-up and relatively small sample size, which may limit the generalizability of its findings.